GLP-1 benefits beyond weight loss
A closer look at semaglutide and the cardiovascular findings from the SELECT trial.
What the research says
In the SELECT trial, semaglutide reduced the relative risk of major cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. The result applies to the population studied; it is not proof of a general longevity effect.
What it doesn’t tell us
Side effects, particularly gastrointestinal symptoms, led some participants to stop treatment. Treatment decisions require a clinician and an individual assessment of benefits and risks.
The original publication
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
New England Journal of Medicine · 2023
Read the original researchThis summary is for education, not medical advice. Speak with a qualified healthcare professional about your individual circumstances. Image is a conceptual illustration.